Sijun Hu, Yong Xie
The First Affiliated Hospital of Nanchang University, Nanchang, China.
Indian J Med Res. 2009 Aug;130(2):115-24.
Vaccination, especially mucosal vaccination, is considered to be effective in the management of Helicobacter pylori infections. However, most antigens alone cannot induce immune responses when administered mucosally and need to be co-administered with adjuvants or delivery systems. The current research on the mucosal adjuvant and delivery systems of vaccine against H. pylori, including advantages and disadvantages, mechanisms and applications is discussed in this review. Mutants of cholera toxin (CT) and the heat labile enterotoxin of Escherichia coli (LT), CpG oligodeoxynucleotides, biocompatible and biodegradable polymers, and live attenuated bacterial vectors may be promising adjuvant and delivery systems for H. pylori vaccine.
疫苗接种，尤其是黏膜疫苗接种，被认为在幽门螺杆菌感染的管理中是有效的。然而，大多数抗原单独经黏膜给药时不能诱导免疫反应，需要与佐剂或递送系统共同给药。本文综述了目前针对幽门螺杆菌疫苗的黏膜佐剂和递送系统的研究，包括其优缺点、作用机制及应用。霍乱毒素（CT）突变体、大肠杆菌不耐热肠毒素（LT）、CpG寡脱氧核苷酸、生物相容性和可生物降解的聚合物以及减毒活细菌载体可能是有前景的幽门螺杆菌疫苗佐剂和递送系统。
